Akero Therapeutics Management

Management Kriterienprüfungen 3/4

Akero Therapeutics CEO ist Andrew Cheng , ernannt in Sep 2018, hat eine Amtszeit von 6.17 Jahren. Die jährliche Gesamtvergütung beträgt $8.83M , bestehend aus 7.5% Gehalt und 92.5% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.71% der Aktien des Unternehmens, im Wert von $15.49M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 5.8 Jahre bzw. 5.6 Jahre.

Wichtige Informationen

Andrew Cheng

Geschäftsführender

US$8.8m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	7.5%
Amtszeit als Geschäftsführer	6.2yrs
Eigentum des Geschäftsführers	0.7%
Durchschnittliche Amtszeit des Managements	5.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	5.6yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Andrew Cheng im Vergleich zu den Einnahmen von Akero Therapeutics verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Sep 30 2024	n/a	n/a	-US$237m
Jun 30 2024	n/a	n/a	-US$204m
Mar 31 2024	n/a	n/a	-US$179m
Dec 31 2023	US$9m	US$660k	-US$152m
Sep 30 2023	n/a	n/a	-US$120m
Jun 30 2023	n/a	n/a	-US$116m
Mar 31 2023	n/a	n/a	-US$112m
Dec 31 2022	US$10m	US$624k	-US$112m
Sep 30 2022	n/a	n/a	-US$121m
Jun 30 2022	n/a	n/a	-US$110m
Mar 31 2022	n/a	n/a	-US$112m
Dec 31 2021	US$4m	US$570k	-US$101m
Sep 30 2021	n/a	n/a	-US$98m
Jun 30 2021	n/a	n/a	-US$95m
Mar 31 2021	n/a	n/a	-US$82m
Dec 31 2020	US$5m	US$523k	-US$79m
Sep 30 2020	n/a	n/a	-US$65m
Jun 30 2020	n/a	n/a	-US$59m
Mar 31 2020	n/a	n/a	-US$50m
Dec 31 2019	US$5m	US$450k	-US$44m
Sep 30 2019	n/a	n/a	-US$90m
Jun 30 2019	n/a	n/a	-US$86m
Mar 31 2019	n/a	n/a	-US$87m
Dec 31 2018	US$1m	US$133k	-US$82m

Vergütung im Vergleich zum Markt: AndrewDie Gesamtvergütung ($USD8.83M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD5.42M).

Entschädigung vs. Einkommen: AndrewDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Andrew Cheng (57 yo)

6.2yrs

Amtszeit

US$8,834,907

Vergütung

Dr. Andrew Cheng, MD, PhD, serves as Director of Vera Therapeutics, Inc. since May 2017. He served as Director of Arbutus Biopharma Corporation since August 17, 2019 until May 25, 2022. He served as Chief...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Andrew Cheng	President	6.2yrs	US$8.83m	0.71% $ 15.5m
Jonathan Young	Co-Founder	6.2yrs	US$3.44m	0.34% $ 7.4m
Timothy Rolph	Co-Founder & Chief Scientific Officer	7.6yrs	US$3.49m	0.20% $ 4.4m
William White	Executive VP	5.6yrs	US$4.29m	0.0027% $ 59.8k
Catriona Yale	Executive VP & Chief Development Officer	6.1yrs	US$3.45m	0.051% $ 1.1m
Scott Gangloff	Chief Technical Officer	less than a year	keine Daten	keine Daten
John Schembri	Senior VP & Head of Finance	less than a year	keine Daten	keine Daten
Patrick Lamy	Senior Vice President of Commercial Strategy	1.8yrs	keine Daten	0.0036% $ 79.0k

5.8yrs

Durchschnittliche Betriebszugehörigkeit

53yo

Durchschnittliches Alter

Erfahrenes Management: AKRODas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (5.8 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Andrew Cheng	President	6.8yrs	US$8.83m	0.71% $ 15.5m
Seth Harrison	Independent Director	5.6yrs	US$568.56k	0.41% $ 8.9m
Jane Pritchett Henderson	Independent Director	5.6yrs	US$586.06k	0% $ 0
Mark Iwicki	Independent Chairman of the Board	6yrs	US$606.06k	0% $ 0
Tomas Heyman	Independent Director	4.4yrs	US$581.06k	0% $ 0
Graham L. Walmsley	Independent Director	6.4yrs	US$578.56k	0.0031% $ 67.6k
Yuan Xu	Independent Director	3.6yrs	US$573.56k	0% $ 0
Judy Chou	Independent Director	3.3yrs	US$571.06k	0% $ 0

5.6yrs

Durchschnittliche Betriebszugehörigkeit

58yo

Durchschnittliches Alter

Erfahrener Vorstand: AKRODie Vorstandsmitglieder gelten als erfahren (5.6 Jahre durchschnittliche Amtszeit).

Akero Therapeutics Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Insider notifies of intention to sell stock

Insider notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Insider notifies of intention to sell stock

Insider notifies of intention to sell stock

Executive VP notifies of intention to sell stock

Recent updates

Akero Therapeutics, Inc. to Showcase New Analyses of Phase 2b Harmony Study in Presentations at 75th Annual AASLD The Liver Meeting®? 2024

Akero Therapeutics, Inc. Provides Business Update

Insider notifies of intention to sell stock

Insider notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Akero Therapeutics: Good Candidate For The MASH Basket

Insider notifies of intention to sell stock

Insider notifies of intention to sell stock

New major risk - Revenue and earnings growth

Executive VP notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

New major risk - Revenue and earnings growth

Insufficient new directors

Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer

Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Akero Therapeutics, Inc

Co-Founder notifies of intention to sell stock

Akero Therapeutics' EFX Data Warrants Caution

Akero Therapeutics, Inc. Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $319 million.

President notifies of intention to sell stock

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $319 million.

Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study

Price target increased by 13% to US$48.38

Akero: Phase 2b NASH Data Bodes Well For Phase 3 SYNCHRONY Program

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Akero Therapeutics, Inc. Announces First Patients Dosed in Efruxifermin Phase 3 Synchrony Program

President exercised options and sold US$368k worth of stock

Co-Founder recently sold US$440k worth of stock

Price target decreased by 29% to US$48.44

Akero Therapeutics, Inc. Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins

New major risk - Share price stability

Akero Therapeutics, Inc. to Present Results from Phase 2B Symmetry Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH

Akero Therapeutics, Inc. Announces Publication of the Harmony Phase 2B Trial Results in the Lancet Gastroenterology & Hepatology

President notifies of intention to sell stock

Price target increased by 7.3% to US$67.75

Price target increased by 7.7% to US$64.75

Insider notifies of intention to sell stock

Akero Therapeutics, Inc. to Report Results of Phase 2b SYMMETRY Study in October 2023

President exercised options and sold US$920k worth of stock

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Akero Therapeutics, Inc.(NasdaqGS:AKRO) dropped from Russell Small Cap Comp Value Index

Co-Founder & Chief Scientific Officer recently sold US$2.1m worth of stock

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

President exercised options and sold US$1.1m worth of stock

Akero Therapeutics, Inc. Releases Topline Data from an Expansion Cohort of the Phase 2B SYMMETRY Study

President exercised options and sold US$1.1m worth of stock

President notifies of intention to sell stock

President exercised options and sold US$1.2m worth of stock

President exercised options and sold US$1.2m worth of stock

Insider notifies of intention to sell stock

Akero Therapeutics, Inc. Announces the Appointment of Patrick Lamy as Senior Vice President, Commercial Strategy

Co-Founder exercised options and sold US$544k worth of stock

Price target increased to US$52.00

Akero Therapeutics, Inc. Completes Enrollment of Phase 2B SYMMETRY Study

President exercised options and sold US$455k worth of stock

Independent Director recently sold US$1.1m worth of stock

President exercised options and sold US$428k worth of stock

Independent Director recently sold US$12m worth of stock

Price target increased to US$48.33

Co-Founder & Chief Scientific Officer exercised options and sold US$299k worth of stock

Akero Therapeutics announces closing of upsized public offering

President notifies of intention to sell stock

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000008 million.

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000008 million.

Akero Therapeutics, Inc. Releases Topline Data from HARMONY

Akero adds over 100% rallying peers after NASH success

Akero Therapeutics, Inc. Announces Results from Cohort C of its Phase 2a BALANCED trial in non-alcoholic steatohepatitis

Price target decreased to US$41.67